| Literature DB >> 33841982 |
Yasir Abu-Omar1, Ibrahim T Fazmin2, Jason M Ali2, Marc P Pelletier1.
Abstract
There is considerable interest and demand in the application of minimally invasive techniques in cardiac surgery driven by multiple factors including patient cosmesis and satisfaction, reduction of surgical trauma and the development of specialized instrumentation that allows these procedures to be performed safely. Minimally invasive mitral valve surgery (MIMVS) has been conducted for more than 25 years and has been shown to offer multiple benefits including better cosmetic results, enhanced post-operative recovery, improved patient satisfaction and most importantly, equivalent clinical outcomes with regards to quality and safety when compared to the standard sternotomy approach. MIMVS may be particularly beneficial in certain subgroups of patients, for example patients undergoing redo mitral valve surgery. In this article, we discuss patient selection criteria for MIMVS, the merits and drawbacks of MIMVS relative to conventional sternotomy approaches, and detail procedural aspects including anaesthetic management, intraoperative technique, and important considerations in myocardial protection and cardiopulmonary bypass (CPB). When considering developing a MIMVS programme, as for any new technique, a team approach to the introduction of the programme is essential. Although it is clear that patient selection is important, particularly early in a surgical programme, with experience complex repairs can be performed through a minimally invasive approach with excellent outcomes. 2021 Journal of Thoracic Disease. All rights reserved.Entities:
Keywords: Mini-thoracotomy; mini-mitral surgery; minimally invasive surgery
Year: 2021 PMID: 33841982 PMCID: PMC8024816 DOI: 10.21037/jtd-20-2114
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Relative contraindications to MIMVS
| Patient characteristic | |
|---|---|
| Cardiac function | • Poor LVEF (<30%) |
| • Severe RV dysfunction | |
| Comorbidities | • Hepatic dysfunction (cirrhosis) |
| • Renal dysfunction (CKD or AKI) | |
| • Significant cerebrovascular disease | |
| Patient body habitus | • Breast implants |
| • Chest wall deformities | |
| • High BMI >40 | |
| Procedural considerations | • Prior right thoracotomy |
| • Simultaneous CABG surgery | |
| Pulmonary system | • Pulmonary hypertension (PA pressure >45 mmHg) |
| • Pulmonary adhesions | |
| Valvular disease | • Aortic regurgitation (moderate or worse) |
| • Mitral annular calcification | |
| • Endocarditis | |
| Vascular system | • Ascending aorta calcification |
| • Dilated ascending aorta | |
| • Aortic aneurysm or dissection | |
| • Grade 4 thoracic aortic disease | |
| • Severe peripheral vascular disease | |
| • Inferior vena cava filter |
Informed by (9,12). MIMVS, minimally invasive mitral valve surgery; AKI, acute kidney injury; BMI, body mass index; CABG, coronary artery bypass graft; CKD, chronic kidney disease; LVEF, left ventricular ejection fraction; PA, pulmonary artery; RV, right ventricular.
Utility of trans-oesophageal echocardiography in MIMVS
| Purpose of TOE | |
|---|---|
| Assessment | • Evaluate biventricular function |
| • Full assessment of the mitral valve pathology | |
| • Identifying any other valvular pathology | |
| Guidance | • Placement of retrograde cardioplegia cannulae into coronary sinus directly, or indirectly through IJV |
| • Positioning femoral venous catheters | |
| • Positioning PA drainage cannulae | |
| • Placement of an IABP | |
| • Position an aortic endoballoon for internal cross-clamping |
Informed by (9,19-21). MIMVS, minimally invasive mitral valve surgery; TOE, transoesophageal echocardiography; IJV, internal jugular vein; PA, pulmonary artery; IABP, intra-aortic balloon pump.
Figure 1Demonstration of the anatomical landmarks and position of incisions and ports for minimally invasive mitral valve surgery.
Figure 2Demonstration of the set-up for minimally invasive mitral valve surgery, with utility port.
Techniques for bypass, aortic cross clamping and myocardial protection during MIMVS
| Techniques | Benefits/use cases | Disadvantages/risks |
|---|---|---|
| Cardiopulmonary bypass | ||
| |
| |
| • Femoral artery (most common) | • Retrograde embolisation into cerebral circulation | |
| • Axillary artery | ||
| |
| |
| • Femoral multistage cannula in SVC | • Additional drainage for patients with large body habitus | |
| • Additional IJV cannula | ||
| Aortic cross clamping | ||
| • Chitwood clamp |
| |
| • Requires additional incision | ||
| • Balloon endoclamp |
|
|
| • Deliver cardioplegia through clamp | • Potential for movement within aorta | |
| • Vent aortic root through clamp | • Requires monitoring of bilateral axillary artery pressures to monitor movement | |
| • Monitor aortic root pressure through clamp | ||
| • Cygnet device (Novare Surgical Systems, USA) |
| |
| • Does not require additional incision | ||
| Myocardial protection | ||
| | ||
| • Both anterograde and retrograde delivery may be used | ||
| |
|
|
| • Standard blood cardioplegia | • Increased myocardial protection to offset myocardial warming from absence of topical cooling | • Increased risk to myocardium due to difficulty in topical myocardial cooling through mini thoracotomy |
| • Long acting cardioplegia (e.g., Del Nido cardioplegia/Custodiol® cardioplegia) | ||
MIMVS, minimally invasive mitral valve surgery; IJV, internal jugular vein.
Figure 3View of the mitral valve during minimally invasive mitral valve surgery following repair.
Figure 4Example of the cosmetic result following minimally invasive mitral valve surgery.
Summary of important outcomes from the meta-analysis by Moscarelli et al. (13)
| Outcome | MIMVS | Sternotomy | P value |
|---|---|---|---|
| Early outcomes | |||
| In hospital mortality | 1% | 1.3% | 0.60 |
| Surgical reopening for bleeding rates | 4% | 2.3% | 0.09 |
| Postoperative stroke rates | 1.1% | 2.1% | 0.50 |
| Length of stay (days) | 7.5 | 7.0 | 0.71 |
| Long term outcomes | |||
| Long term mortality | 0.7% | 1% | 0.46 |
| Long term stroke rates | 0.2% | 0.7% | 0.20 |
| Intraoperative differences | |||
| Mean CPB time (minutes) | 129.2 | 97 | 0.01 |
| Mean cross clamp time (minutes) | 85.6 | 63.4 | 0.01 |
| Procedure success | |||
| Failed repair rates | 1.6% | 3% | 0.66 |
MIMVS, minimally invasive mitral valve surgery; CPB, cardiopulmonary bypass.